Evidence map›Paper›PMID 36597018›Full record

ArticleClinical and molecular hepatology2023

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.

Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti and 4 more

Abstract read
In one paragraph

Article in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Food science & nutrition · 2025
    Article
  17. Novel Therapeutics for Hepatocellular Carcinoma.Clinics in liver disease · 2025
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sungchul ChoiYonsei University College of Medicine, Seoul, Korea.
Beom Kyung KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Dong Keon YonDepartment of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Korea.
Seung Won LeeDepartment of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea.
Han Gyeol LeeYonsei University College of Medicine, Seoul, Korea.
Ho Hyeok ChangYonsei University College of Medicine, Seoul, Korea.
Seoyeon ParkYonsei University College of Medicine, Seoul, Korea.
Ai KoyanagiResearch and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Dr. Antoni Pujadas, Barcelona, Spain.
Louis JacobResearch and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Dr. Antoni Pujadas, Barcelona, Spain.
Elena DragiotiPain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden.
Joaquim RaduaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERSAM, Instituto de Salud Carlos III, University of Barcelona, Barcelona, Spain.
Jae Il ShinDepartment of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
Seung Up KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Lee SmithCentre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, UK.

Funding

Ministry of Science, ICT and Future PlanningMinistry of Trade, Industry and Energy 20013712National Research Foundation of Korea 2019R1A2C4070136National Research Foundation of Korea 2021R1I1A2059735
6 · The paper itself

Abstract

BACKGROUND/

aimsGlobal distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in 204 countries and territories from 1990 to 2019.

methodsThe Global Burden of Disease 2019 report was used for statistical analysis. In addition, we performed stratification analysis to five quintiles using sociodemographic index and 21 geographic regions.

resultsThe crude numbers of liver cancer disease-adjusted life years (DALYs) and deaths significantly increased during the study period (DALYs; 11,278,630 in 1990 and 12,528,422 in 2019, deaths; 365,215 in 1990 and 484,577 in 2019). However, the Age-standardized DALY and mortality rates decreased. Hepatitis B virus (HBV) remains the leading cause of liver cancer DALYs and mortality, followed by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD). Although Age-standardized DALY and mortality rates of liver cancer due to HBV and HCV have decreased, the rates due to alcohol consumption and NASH/NAFLD have increased. In 2019, the population of the East Asia region had the highest Age-standardized DALY and mortality rates, followed by high-income Asia-Pacific and Central Asia populations. Although East Asia and high-income Asia-Pacific regions showed a decrease during the study period, Age-standardized DALY rates increased in Central Asia. High-income North American and Australasian populations also showed a significant increase in Age-standardized DALY.

conclusionLiver cancer remains an ongoing global threat. The burden of liver cancer associated with alcohol consumption and NASH/NAFLD is markedly increasing and projected to continuously increase.

Indexed as

Hepatitis CLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseFemaleGlobal Burden of DiseaseHumansIncidenceMaleQuality-Adjusted Life YearsSex CharacteristicsAetiologyGlobal burdenIncidenceMortalityPrimary liver cancer

Identifiers

PMID36597018
PMCPMC10121317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.